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Metaplastic breast carcinoma (MBC) is an uncommon malignancy characterized by the co-existence of two or more
cellular types, commonly a mixture of epithelial and mesenchymal components. A case of a female patient aged 46
years with MBC (carcinosarcoma) is presented, including mammographic, ultrasonic, gross examination, and
pathological findings. After undergoing modified radical mastectomy of the left breast and subsequent six courses
of adjuvant chemotherapy and endocrine therapy, the patient is now doing well with no recurrence and metastasis.
Conventional treatments for invasive ductal carcinoma (IDC) may appear to be less effective. Patients with MBC
would be appropriate candidates for innovative or targeted therapy regimens.
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Metaplastic breast carcinoma (MBC) is a rare and heteroge-
neous group of malignancies that constitutes less than 1%
of all breast cancers [1-3]. The World Health Organization
recognized and classified metaplastic carcinoma in 2003
[4]. We report our experience with a case of a 46-year-old
female who had a mixed epithelial and mesenchymal meta-
plastic carcinoma (carcinosarcoma) of the left breast, and
we also present here a short review of the literature.
Case presentation
A 46-year-old woman with two lumps in the upper outer
quadrant of the left breast was referred to our department.
The patient complained that the painless lumps have been
growing rapidly over the previous three weeks. She had no
history of trauma, nipple discharge, or other previous
breast diseases. There was no known family history of
breast cancer.
On clinical examination, palpation revealed two firm
and mobile lumps closely adjacent to each other, meas-
uring about 4.0 × 4.0 cm and 3.0 × 3.0 cm, respectively.* Correspondence: xyzheng@mail.cmu.edu.cn
1Department of Breast Surgery, the First Affiliated Hospital, China Medical
University, North Nanjing Street 155, Shenyang 110001, P.R. China
4Lab 1, Cancer Institute, China Medical University, North Nanjing Street 155,
Shenyang 110001, China
Full list of author information is available at the end of the article
© 2014 Kang et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.There was no dimpling or puckering of the skin or
changes of the skin color and the nipple. Axillary lymph
nodes and other superficial lymph nodes were not palpable.
Contralateral breast and axilla were normal.
Mammography revealed two well-circumscribed, round
masses in the upper outer quadrant of the left breast,
measuring 4.7 × 4.5 cm and 4.2 × 3.8 cm, respectively. The
masses were generally high density, accompanied by het-
erogeneous micro-calcifications. The lesion corresponded
to category 4B according to the BI-RADS Mammography
lexicon classification [5] (Figure 1). Ultrasound demon-
strated a pear-shaped, complex echoic lesion measuring
approximately 8.3 × 3.7 × 7.3 cm with relatively indistinct
margins in the upper outer quadrant of the left breast.
One hypoechoic mass at the 2 o’clock position of the lesion
was accompanied by a hyperechoic area with abundant
vessels within the mass. The 3 o’clock mass of the lesion
was hyperechoic with spotted blood flow. No enlarged
lymph nodes were detected. An ultrasound diagnosis
of intraductal papilloma accompanied by hemorrhage
and solid mass (BI-RADS 4) [5] was made (Figure 2). The
whole lesion was blue colored, with an elasticity score of 4
(Figure 3). Though no lymph nodes were detected in either
clinical or ultrasonic examination, the patient did not agree
with substituting axillary lymph node dissection (ALND) by
sentinel lymph node biopsy (SLNB). Thus, modified radicald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Mammograms demonstrate two high-density masses. A. Left craniocaudal mammogram shows two well-circumscribed round
masses with internal heterogeneous micro-calcifications. B. Left mediolateral oblique mammogram shows two high-density masses in the upper
outer quadrant of the left breast.
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ation of the specimen revealed a cystic-solid tumor with
complete envelope, which consisted of two parts. The
tumor was measured 7.0 cm in length and width, and
5.0 cm in height with the solid part measured 4.0 × 4.0 ×
3.5 cm. Dark-red intracystic hemorrhage was noted (Fig-
ure 4). Microscopically, the tumor exhibited a biphasic pat-
tern consisting of epithelial and mesenchymal components.
Intraductal cell masses were formed in the epithelial com-
ponents with obvious heteromorphism and central necro-
sis. Meanwhile, a large number of spindle cells with some
multinucleate giant cells were present in the mesenchymal
components in an interlaced pattern (Figure 5). Patho-
logical diagnosis was mixed epithelial and mesenchymal
metaplastic carcinoma (carcinosarcoma, histological grade
III). No metastasis was found in 15 lymph nodes.
Immunohistochemically (images not included), the breast
tumor showed negative for Cytokeratin (CK, CK5/6,
and CK7), Desmin, S-100, and CD34 but showed positive
for Vimentin, SMA, and CD68. However, the epithelial
components expressed positive estrogen receptor (ER),
progesterone receptor (PR), and C-erbB-2. In contrast,
estrogen and progesterone receptors were negative, with
weakly positive C-erbB-2, in the mesenchymal components.
Ki-67 expression was 20%.Having undergone three cycles of CEF (cyclophosphamide,
epirubicin, and fluorouracil) and three cycles of T (Taxotere)
followed by Tamoxifen, the patient is doing well one year
after surgery with no recurrence and metastasis.
Discussion
Accounting for less than 1% of breast cancers diagnosed
annually [1-3], metaplastic breast carcinoma (MBC) is
known to be characterized by the presence of two or more
cellular elements histologically, commonly a mixture of
epithelial and mesenchymal components [6-10]. Wargotz
and Norris suggested that carcinosarcoma of the breast, in
which an epithelial-mesenchymal transition zone does not
exist, should be distinguished from other MBC diseases.
Such diagnosis is not difficult with detailed histological
investigation [7]. Classification of metaplastic carcinoma
was proposed by the World Health Organization in 2003
as 1) squamous cell carcinoma, 2) adenocarcinoma with
spindle cell proliferation, 3) adenosquamous, including
mucoepidermoid, and 4) mixed epithelial and mesenchy-
mal. Subtypes of mixed epithelial and mesenchymal carcin-
oma includes a) carcinoma with chondroid metaplasia, b)
carcinoma with osseous metaplasia, and c) carcinosarcoma
[4]. Carcinosarcoma is a general term describing biphasic
lesions that simultaneously contain malignant epithelial
Figure 2 A 46-year-old woman with palpable masses in the left breast. A. Ultrasound demonstrates a pear-shaped complex echoic lesion with
relatively indistinct margins. B. A hyperechoic area with abundant vessels within the mass. Another mass of the lesion is hyperechoic with spotted blood flow.
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origin of breast carcinosarcoma is far from clear. They have
been reported to develop from existing cystosarcoma phyl-
lodes, fibroadenoma and cystic backgrounds [12-14]. Carci-
nosarcoma is characterized by the loss of intercellular
adhesion, down-regulation of epithelial makers (cytokera-
tins), upregulation of mesenchymal markers [vimentin and
smooth muscle actin (SMA)], increase in motility, inva-
siveness, and metastatic capabilities [15-19].
Although relatively rare and histologically heterogeneous,
their clinical manifestations are often similar. They are often
palpable, mobile, and large, showing benign imaging fea-
tures such as a round or oval shape with circumscribed
margins. Meanwhile, estrogen, progesterone, and Her-2 are
less frequently shown to be positive, with lower rates of axil-
lary node involvement [20-24]. But approximately 70% of
metaplastic carcinomas show epidermal growth factor re-
ceptor (EGFR) gene amplification and overexpression [25].The optimal treatment strategies for MBC are unknown.
Currently, management of MBC has largely paralleled that
of invasive ductal carcinoma (IDC). Theoretically, MBC
patients should undergo mastectomy rather than lumpec-
tomy due to larger masses compared to their IDC coun-
terparts. However, studies have found no difference in
overall or disease-free survival between patients with
MBC undergoing either modified radical mastectomy or
breast conservation therapy [26,27]. Traditional adjuvant
chemotherapy for IDC is ineffective against MBC [28-30],
so is hormonal therapy as there is a high incidence of
hormone receptor negativity in MBC [31]. Tseng et al.
suggested that adjuvant radiation improved both overall
and disease-specific survival for all patients undergoing
treatment for MBC, regardless of the type of operation per-
formed (lumpectomy versus mastectomy) [26]. Treatment
given in the neoadjuvant setting has become the standard
approach for potentially operable breast carcinomas with
Figure 3 Left breast elastography shows the whole lesion was blue colored.
Figure 4 Gross examination shows a cystic-solid tumor, which
consisted of two parts. Dark-red hemorrhage is noted.
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micrometastatic disease, and the ability to assess respon-
siveness to therapy directly. However, it is important to
identify patients who would benefit from this approach and
those who would not. We should be cautious when consid-
ering neoadjuvant chemotherapy given to those with MBC
because several studies indicated that these patients
responded poorly and might gain less benefit from standard
regimens [20,32,33]. In addition, samples obtained by either
fine needle aspiration or core needle biopsy might not be
sufficient to distinguish MBC from common types of breast
cancer, which suggests that it could be difficult to make an
accurate diagnosis preoperatively [21,34,35]. Therefore,
conventional neoadjuvant regimens, if given to patients
with MBC, may carry the risks of tumor progression.
Takuwa et al. reported a case of MBC that responded well
to platinum-based neoadjuvant chemotherapy, resulting in
nearly a pathologically complete response [36]. Neverthe-
less, careful monitoring is essential since the failure of
chemotherapy may result in clinical deterioration and
preoperative complications. Under the circumstance of
ineffectiveness of conventional therapies, innovative or
targeted treatments are being explored. Since MBC
tends to be EGFR positive while Her-2 tends to be nega-
tive, Leibl and Moinfar suggested that targeted protein
kinase inhibitors such as gefitinib might be effective
[25].
Figure 5 Epithelial and mesenchymal components are shown together (hematoxylin and eosin (HE) ×20).
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Some studies reported that compared to patients with
IDC, those with MBC have a worse prognosis. Their
overall survival and disease-free survival are both de-
creased despite presenting more commonly as node-
negative disease [37,38]. Conversely, other studies showed
comparable outcomes with matched typical breast cancer
[2,21]; however, almost all MBC recurrences happened
during the first five years, whereas recurrence curves for
IDC continued to fall over time, suggesting the possibility
that MBC may show an earlier recurrence than IDC [21].
Conclusions
Generally, MBC is often palpable, mobile, and large, show-
ing a round or oval-shaped mass with a circumscribed mar-
gin in the mammogram. Given the heterogeneity of MBC,
an accurate preoperative diagnosis may not be achieved
with needle biopsies. Conventional treatments for IDC also
appear to be less effective. Patients with MBC would be ap-
propriate candidates for innovative or targeted therapy regi-
mens. Prospective studies are needed, but the rarity of
MBC makes these less likely to be conducted.
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